Atezolizumab with erlotinib in combination treatment for EGFR mutant NSCLC
Charles Rudin MD, PhD of the Memorial Sloan Kettering Cancer Center, New York, NY discusses targeted therapies, immunotherapy and their combination in non-small cell lung cancer (NSCLC) therapy. Targe...
Author: VJOncology
Added: 02/14/2017
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
More News: Cancer | Cancer & Oncology | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Tarceva